Skip to content
value.today

MapLight Therapeutics, Inc.

MPLT
$558 Mmarket cap on Sep 15, 2026
Compare
World rank
#12,083
Revenue
—
For year ending December-2025
Net income
$-161 M
SEC filing
Employees
133
As of December 31, 2025
SEC filing

MapLight Therapeutics, Inc. in brief

MapLight Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Redwood City, California, USA. Its market value was $558 M on 15 September 2026, which makes it the 12,083rd largest listed company in the world and the 2,460th largest in the USA on this site. It employs about 133 people and Christopher A. Kroeger is its chief executive. Its shares trade under the symbol MPLT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About MapLight Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers.

From the company's annual report filed with the US SEC: read the report

MapLight Therapeutics, Inc. timeline

3 events, 2019–2025
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed MapLight Therapeutics, Inc.
    Formerly Alvarado Therapeutics, Inc..
  4. 2025
  5. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of MapLight Therapeutics, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$151 M$301 M$452 M$603 M

World rank over time

▼ down 165 places since 2026
2026-08-01: #12009#12,00920262026-09-15: #12174#12,1742026

Rank in USA: #2,494 (Aug 2026) · #2,458 (Sep 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.2×
Free cash flow yield
-24.8%
Net margin
—
Operating margin
—
Return on equity
-35.2%
Liabilities / assets
4.4%
Profit per employee
$-1.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue —, net income $-78M—FY24Fiscal year ending Dec 2025: revenue —, net income $-161M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-169M$-161M—
Dec 2024——$-83M$-78M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-138M$0M$-139M$-18.56—
Dec 2024$-79M$1M$-80M$-105.38—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-19M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-21M—Dec ’24Three months to Mar 2025: revenue —, net income $-22M—Mar ’25Three months to Jun 2025: revenue —, net income $-30M—Jun ’25Three months to Sep 2025: revenue —, net income $-29M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-80M—Dec ’25Three months to Mar 2026: revenue —, net income $-61M—Mar ’26Three months to Jun 2026: revenue —, net income $-60M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-60M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of MapLight Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-169 M
Net income
$-161 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$480 M
Total liabilities
$21 M
Total equity
$458 M

As of December-2025

Top 98 institutional investors in MapLight Therapeutics, Inc.#

As of Sep 30, 2026
98 institutions held 31.1 M shares (about 73.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 47.7%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in MapLight Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Fcpm III Services B.V.4,428,328+1,201,928 (+37.25%)10.44%$45 MNov 16, 2026
2Goldman Sachs Group Inc3,599,556+1,651,244 (+84.75%)8.48%$37 MNov 16, 2026
3Nan Fung Group Holdings Ltd2,300,328+1,329,075 (+136.84%)5.42%$23 MNov 13, 2026
4Novo Holdings A/s2,086,622-1,600,000 (-43.40%)4.92%$21 MNov 16, 2026
5BlackRock, Inc.1,712,729+687,595 (+67.07%)4.04%$17 MNov 13, 2026
6FMR LLC1,541,940+718,384 (+87.23%)3.63%$16 MNov 10, 2026
7Deep Track Capital, LP1,318,101New3.11%$13 MNov 16, 2026
8Baker Bros. Advisors LP1,166,763+802,058 (+219.92%)2.75%$12 MNov 16, 2026
9Price T Rowe Associates Inc /MD/1,132,288-290,647 (-20.43%)2.67%$12 MNov 16, 2026
10T. Rowe Price Investment Management, Inc.945,216-1,836,512 (-66.02%)2.23%$10 MNov 16, 2026
11Sanofi912,0410 (0.00%)2.15%$9 MNov 5, 2026
125AM Venture Management, LLC741,893-208,118 (-21.91%)1.75%$8 MNov 16, 2026
13ADAR1 Capital Management, LLC725,165+698,668 (+2636.78%)1.71%$7 MNov 16, 2026
14Velan Capital Investment Management LP624,703+131,810 (+26.74%)1.47%$6 MNov 16, 2026
15Marshall Wace, LLP612,310+606,510 (+10457.07%)1.44%$6 MNov 13, 2026
16Pivotal bioVenture Partners Investment Advisor LLC611,4460 (0.00%)1.44%$6 MNov 13, 2026
17Blue Owl Capital Holdings LP556,371-173,558 (-23.78%)1.31%$6 MNov 13, 2026
18Two Sigma Investments, LP516,022+507,024 (+5634.85%)1.22%$5 MNov 16, 2026
19Geode Capital Management, LLC440,731+38,680 (+9.62%)1.04%$4 MNov 6, 2026
20Point72 Asset Management, L.P.426,261New1.00%$4 MNov 16, 2026
21Millennium Management LLC423,678+294,837 (+228.84%)1.00%$4 MNov 16, 2026
22Capital World Investors415,760+30 (+0.01%)0.98%$4 MNov 12, 2026
23Vanguard Capital Management LLC396,076-388,074 (-49.49%)0.93%$4 MNov 13, 2026
24Trexquant Investment LP363,736+299,944 (+470.19%)0.86%$4 MNov 16, 2026
25State Street Corp313,586-538,564 (-63.20%)0.74%$3 MNov 12, 2026
Show all 98: investors 26 to 98
Institutional investors 26 to 98 in MapLight Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Lazard Asset Management LLC263,905+183,823 (+229.54%)0.62%$3 MNov 16, 2026
27BNP Paribas Financial Markets245,219+174,735 (+247.91%)0.58%$2 MNov 12, 2026
28BNP PARIBAS ASSET MANAGEMENT Holding S.A.170,8620 (0.00%)0.40%$2 MNov 13, 2026
29DAFNA Capital Management LLC155,579-15,427 (-9.02%)0.37%$2 MNov 16, 2026
30TD Asset Management Inc140,888+86,362 (+158.39%)0.33%$1 MNov 13, 2026
31Northern Trust Corp129,095+12,443 (+10.67%)0.30%$1 MNov 16, 2026
32Charles Schwab Investment Management Inc122,473-14,345 (-10.48%)0.29%$1 MNov 16, 2026
33Vanguard Portfolio Management LLC120,871+24,110 (+24.92%)0.28%$1 MNov 13, 2026
34Superstring Capital Management LP118,304-7,128 (-5.68%)0.28%$1 MNov 16, 2026
35Vanguard Fiduciary Trust Co116,464-6,671 (-5.42%)0.27%$1 MNov 13, 2026
36UBS Group AG102,232-19,796 (-16.22%)0.24%$1 MNov 10, 2026
37Barclays PLC85,813+72,838 (+561.37%)0.20%$1 MNov 6, 2026
38Citadel Advisors LLC85,475+59,724 (+231.93%)0.20%$1 MNov 16, 2026
39HRT Financial LP83,737+31,754 (+61.09%)0.20%$1 MNov 13, 2026
40Manufacturers Life Insurance Company, The83,274+76,234 (+1082.87%)0.20%$1 MNov 13, 2026
41Quadrature Capital Ltd74,485New0.18%$1 MNov 13, 2026
42XTX Topco Ltd63,396+38,477 (+154.41%)0.15%$1 MNov 16, 2026
43Morgan Stanley60,716+22,412 (+58.51%)0.14%$1 MNov 13, 2026
44Citigroup Inc59,173+42,122 (+247.04%)0.14%$1 MNov 4, 2026
45Jump Financial, LLC58,461+33,239 (+131.79%)0.14%$1 MNov 13, 2026
46Schonfeld Strategic Advisors LLC54,016New0.13%$1 MNov 16, 2026
47Nuveen, LLC30,957+13,036 (+72.74%)0.07%$0 MNov 10, 2026
48Bank of New York Mellon Corp30,218-192 (-0.63%)0.07%$0 MNov 5, 2026
49D. E. Shaw & Co., Inc.29,369New0.07%$0 MNov 16, 2026
50Gsa Capital Partners LLP29,193New0.07%$0 MNov 16, 2026
51HSBC Holdings PLC27,937New0.07%$0 MNov 16, 2026
52Ghisallo Capital Management LLC20,0000 (0.00%)0.05%$0 MNov 16, 2026
53Engineers Gate Manager LP18,952New0.04%$0 MNov 16, 2026
54Axq Capital, LP18,928New0.04%$0 MNov 12, 2026
55Susquehanna International Group, LLP18,698New0.04%$0 MNov 16, 2026
56Bank Of America Corp /de/16,094-38,370 (-70.45%)0.04%$0 MNov 16, 2026
57Alliancebernstein L.P.15,880New0.04%$0 MNov 16, 2026
58Squarepoint Ops LLC15,735New0.04%$0 MNov 9, 2026
59Rhumbline Advisers14,156-1,592 (-10.11%)0.03%$0 MNov 10, 2026
60Market Street Wealth Management Advisors LLC14,1240 (0.00%)0.03%$0 MOct 9, 2026
61Jane Street Group, LLC13,286New0.03%$0 MNov 12, 2026
62Jpmorgan Chase & Co11,823+7,491 (+172.92%)0.03%$0 MNov 12, 2026
63Virtus Investment Advisers, LLC11,435-356 (-3.02%)0.03%$0 MNov 12, 2026
64MA Private Wealth10,3890 (0.00%)0.02%$0 MNov 10, 2026
65LMR Partners LLP10,0000 (0.00%)0.02%$0 MNov 16, 2026
66Deutsche Bank AG\9,019-1,307 (-12.66%)0.02%$0 MNov 6, 2026
67Vanguard Global Advisers, LLC7,533-895 (-10.62%)0.02%$0 MNov 13, 2026
68Russell Investments Group, Ltd.7,321+54 (+0.74%)0.02%$0 MNov 6, 2026
69Tower Research Capital LLC (TRC)6,917+4,921 (+246.54%)0.02%$0 MNov 16, 2026
70MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.6,200-211 (-3.29%)0.01%$0 MNov 16, 2026
71New York State Common Retirement Fund5,3000 (0.00%)0.01%$0 MNov 17, 2026
72Wells Fargo & Company/mn3,768-5,651 (-60.00%)0.01%$0 MNov 16, 2026
73Global Retirement Partners, LLC3,367+3,304 (+5244.44%)0.01%$0 MNov 10, 2026
74Police & Firemen's Retirement System of New Jersey2,300-3,191 (-58.11%)0.01%$0 MNov 9, 2026
75SBI Securities Co., Ltd.1,709+549 (+47.33%)0.00%$0 MOct 22, 2026
76Simplex Trading, LLC1,456+918 (+170.63%)0.00%$0 MNov 4, 2026
77Caitong International Asset Management Co., Ltd1,265+715 (+130.00%)0.00%$0 MOct 29, 2026
78Legal & General Group Plc1,0330 (0.00%)0.00%$0 MNov 16, 2026
79Ameritas Investment Partners, Inc.9460 (0.00%)0.00%$0 MNov 13, 2026
80Royal Bank Of Canada696+222 (+46.84%)0.00%$0 MNov 16, 2026
81Fifth Third Bancorp574New0.00%$0 MNov 5, 2026
82Jones Financial Companies Lllp409New0.00%$0 MNov 13, 2026
83Osaic Holdings, Inc.375-1,523 (-80.24%)0.00%$0 MNov 12, 2026
84Sterling Capital Management LLC331+275 (+491.07%)0.00%$0 MOct 22, 2026
85PNC Financial Services Group, Inc.316+222 (+236.17%)0.00%$0 MNov 6, 2026
86Farther Finance Advisors, LLC282+162 (+135.00%)0.00%$0 MOct 8, 2026
87State of Wyoming238-123 (-34.07%)0.00%$0 MOct 28, 2026
88GAMMA Investing LLC190+67 (+54.47%)0.00%$0 MOct 8, 2026
89California State Teachers Retirement System1440 (0.00%)0.00%$0 MNov 13, 2026
90Fortitude Family Office, LLC76New0.00%$0 MOct 14, 2026
91UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC42New0.00%$0 MNov 16, 2026
92Arax Advisory Partners18-15 (-45.45%)0.00%$0 MNov 12, 2026
93EverSource Wealth Advisors, LLC18+10 (+125.00%)0.00%$0 MNov 4, 2026
94CoreCap Advisors, LLC9New0.00%$0 MOct 8, 2026
95Covestor Ltd9-7 (-43.75%)0.00%$0 MOct 30, 2026
96Ascentis Wealth Management, LLC8New0.00%$0 MNov 3, 2026
97Allworth Financial LP2-5 (-71.43%)0.00%$0 MNov 17, 2026
98Silver Grove Financial Group, Inc.2New0.00%$0 MNov 5, 2026

Mutual funds holding MapLight Therapeutics, Inc.#

117 funds hold shares worth $211 M (about 16.8% of the company). Since their previous reports 52 added shares and 49 sold, buying $75 M net.
Mutual funds holding MapLight Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc.625,046$22 M1.5%0.24%−0.1%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.605,601$22 M1.5%0.21%−2.5%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.552,279$20 M1.3%<0.01%+15%Jun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.498,428$18 M1.2%0.17%newJun 30, 2026
🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc404,389$14 M0.99%0.02%newJun 30, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc.402,792$14 M0.98%0.15%newJun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.398,809$14 M0.97%0.10%+750%Jun 30, 2026
🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc.342,343$12 M0.84%0.24%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors267,770$10 M0.65%0.01%−42%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.216,312$8 M0.53%<0.01%−4.1%Jun 30, 2026
🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC406,402$5 M0.99%0.07%newJul 31, 2026
🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC263,529$3 M0.64%0.07%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC103,544$3 M0.25%<0.01%+27%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors83,819$3 M0.20%0.02%+1.3%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.99,384$3 M0.24%0.02%+19%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.94,698$3 M0.23%0.01%+26%May 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC202,900$3 M0.50%0.12%no changeJul 31, 2026
🇺🇸 T. Rowe Price Small-Mid Cap ETFT. Rowe Price Associates, Inc.63,511$2 M0.16%0.08%newJun 30, 2026
🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC138,400$2 M0.34%0.11%newJul 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.131,368$2 M0.32%<0.01%newJul 31, 2026
🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC45,267$2 M0.11%0.14%newJun 30, 2026
🇺🇸 Small Cap Value PortfolioMason Street Advisors, LLC42,858$2 M0.10%0.23%no changeJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.42,357$2 M0.10%0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC114,415$1 M0.28%<0.01%−40%Jul 31, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC50,257$1 M0.12%0.02%newMay 29, 2026
🇺🇸 Small-Cap Value FundBridgeway Capital Management, LLC35,000$1 M0.09%0.37%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors34,702$1 M0.08%0.08%−29%Jun 30, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc.32,604$1 M0.08%0.06%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC39,111$1 M0.10%<0.01%+23%May 31, 2026
🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc.29,135$1 M0.07%0.14%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC30,430$1 M0.07%<0.01%+22%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC29,346$1 M0.07%<0.01%+11%May 31, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC21,112$1 M0.05%0.07%newJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC19,495$1 M0.05%0.01%−32%Jun 30, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc.23,178$1 M0.06%0.02%no changeMay 31, 2026
🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC23,000$1 M0.06%<0.01%newMay 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.15,384$1 M0.04%0.03%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC13,151$0 M0.03%0.01%−7.0%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC11,760$0 M0.03%0.01%−44%Jun 30, 2026
🇺🇸 SMALLCAP World FundCapital Research and Management Company11,341$0 M0.03%0.02%newJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors11,224$0 M0.03%<0.01%−86%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.25,379$0 M0.06%<0.01%−40%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC8,606$0 M0.02%0.02%+11%Jun 30, 2026
🇺🇸 Small Company Value TrustJohn Hancock Variable Trust Advisers LLC8,524$0 M0.02%0.20%no changeJun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.10,329$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.8,330$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.9,486$0 M0.02%0.02%+17%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.7,297$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.7,200$0 M0.02%<0.01%+9.1%Jun 30, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc.7,636$0 M0.02%0.01%−8.0%May 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC16,937$0 M0.04%0.04%newJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company7,465$0 M0.02%0.02%no changeMay 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation5,900$0 M0.01%<0.01%−42%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.7,044$0 M0.02%0.02%+21%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.5,082$0 M0.01%0.01%−47%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC13,865$0 M0.03%<0.01%−40%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC4,526$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC4,464$0 M0.01%0.03%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.11,837$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc.5,103$0 M0.01%<0.01%−5.9%May 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC4,064$0 M<0.01%0.01%−31%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC4,040$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC4,040$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.3,895$0 M<0.01%0.04%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC10,157$0 M0.02%<0.01%−1.7%Jul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC3,632$0 M<0.01%0.01%−37%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust4,414$0 M0.01%<0.01%newMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.3,476$0 M<0.01%<0.01%+7984%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION3,800$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC3,036$0 M<0.01%0.01%−45%Jun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC2,976$0 M<0.01%0.03%newJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.2,576$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC6,932$0 M0.02%<0.01%−0.1%Jul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS2,348$0 M<0.01%0.01%−40%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,340$0 M<0.01%0.04%−32%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC2,215$0 M<0.01%0.01%−38%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,041$0 M<0.01%0.02%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,907$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC4,990$0 M0.01%<0.01%−41%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC1,787$0 M<0.01%<0.01%−84%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.1,639$0 M<0.01%0.01%−40%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC1,617$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.1,590$0 M<0.01%0.01%−26%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,831$0 M<0.01%<0.01%+38%May 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,427$0 M<0.01%0.01%−31%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC1,282$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,221$0 M<0.01%0.02%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC2,892$0 M<0.01%<0.01%−4.0%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management946$0 M<0.01%0.01%−31%Jun 30, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC929$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Moderate Allocation PortfolioT. Rowe Price Associates, Inc.895$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC834$0 M<0.01%0.01%−38%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC815$0 M<0.01%0.02%no changeJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC910$0 M<0.01%0.01%+24%May 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC1,888$0 M<0.01%<0.01%−29%Jul 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC674$0 M<0.01%<0.01%−3.2%Jun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC633$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,677$0 M<0.01%<0.01%+19%Jul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC723$0 M<0.01%<0.01%−31%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC712$0 M<0.01%<0.01%−32%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at MapLight Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$66.2 M
10 purchases, 4 insiders
Sold, 12 months
$30.2 M
145 sales, 8 insiders
Net, 12 months
$36.0 M
open market only
Insiders on file
16
since
$108.7 M-$11.5 M$0Oct 2025: bought $108.7 M (2 trades), sold $0 (0 trades)Oct 25Jan 2026: bought $0 (0 trades), sold $636 K (4 trades)Feb 2026: bought $694 K (4 trades), sold $732 K (9 trades)FebApr 2026: bought $0 (0 trades), sold $4.7 M (26 trades)May 2026: bought $0 (0 trades), sold $11.5 M (54 trades)MayJul 2026: bought $15.5 M (5 trades), sold $11.2 M (44 trades)Aug 2026: bought $50.1 M (1 trades), sold $277 K (1 trades)AugSep 2026: bought $0 (0 trades), sold $193 K (1 trades)Oct 2026: bought $0 (0 trades), sold $1.1 M (6 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
MapLight Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Christopher A. KroegerChief Executive Officer, DirectorSell-73,691$8.080$595 K1.20 MForm 4
filed Jonathan GillisCAO and Interim CFOSell-10,167$8.080$82 K142,315Form 4
filed James Woodruff LillieChief Scientific OfficerSell-11,513$8.080$93 K198,597Form 4
filed Kristopher HansonGeneral CounselSell-9,020$8.080$73 K128,024Form 4
filed Erin Pennock FoffChief Medical OfficerSell-15,355$8.080$124 K296,906Form 4
filed Anatol KreitzerChief Discovery OfficerSell-12,248$7.840$96 K168,678Form 4
filed Kristopher HansonGeneral CounselSell10b5-1 plan-16,509$11.67$193 K137,044Form 4
filed James Woodruff LillieChief Scientific OfficerGrant or award+7,730——210,110Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: MapLight Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.3 M
7.4% of shares · 10.31 days to cover
Shares sold short, last 24 reportsAll stocks →

IPO: registered (S-1), not yet priced · IPO calendar

Stock splits: 1-for-16.81 reverse split

Fails to deliver

  • : 165 shares at $7.97
  • : 42,158 shares at $8.16
  • : 3,314 shares at $7.81
  • : 43 shares at $13.15
  • : 3,752 shares at $13.71

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

MapLight Therapeutics, Inc. scorecard#

Passes 1 of the 4 checks that could be worked out. Fiscal year 2025; market cap of Sep 15, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-09-15, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-09-15, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-09-15, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-09-15, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-09-15, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-09-15, more than 60 days ago.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-18.56 vs -105.38Diluted EPS -18.56 in fiscal 2025 against -105.38 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$161 MNet income -$161 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-121.7%-121.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities20.0×Current ratio 20.00 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-09-15, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

MapLight Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

MapLight Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024
Income statement
Research and development13869
General and administrative3114
Operating expenses16983
Operating income−169−83
Interest and finance income5.54.5
Other non-operating income (expense)7.95.4
Net income attributable to shareholders−161−78
Earnings per share, basic-18.56-105.38
Earnings per share, diluted-18.56-105.38
Shares, weighted average (basic)8.70.7
Shares, weighted average (diluted)8.70.7
Balance sheet
Cash and cash equivalents4738
Short-term investments25871
Other current assets205.8
Current assets325115
Property, plant and equipment1.11.2
Right-of-use (leased) assets5.56.4
Long-term investments14811
Total assets480137
Accounts payable3.31.9
Current liabilities1616
Lease liabilities (non-current)4.95.8
Non-current liabilities—5.8
Total liabilities2122
Retained earnings−361−199
Shareholders' equity458−194
Total liabilities and equity480137
Shares outstanding440.8
Cash-flow statement
Share-based compensation361.1
Cash from operating activities−138−79
Capital expenditure−0.5−0.8
Cash from investing activities−323−81
Cash from financing activities470118
Report10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at MapLight Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 5

MapLight Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share saleResults announced8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Unregistered share saleBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 13, 2026

Acquisitions and funding#

6 private funding rounds before listing

Private share sales · funding history

Private share sales of MapLight Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$188 MNo. 6$50 to $250 million19equitySEC
Jul 2023$105 MNo. 5$50 to $250 million12equitySEC
Oct 2022$12 MNo. 4$10 to $50 million1equitySEC
Feb 2021$30 MNo. 3$10 to $50 million2equitySEC
Aug 2019$16 MNo. 2$10 to $50 million2equitySEC
Feb 2019$5 MNo. 1$2 to $10 million2equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at MapLight Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $160 K a year.

Certified, FY2025
1
#2,033 among companies on value.today
Worker positions
1
Median wage offered
$160 K
a year, full-time
Applications filed
1
MapLight Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Senior Scientist, Formulation DevelopmentChemists1$160 K

Where: San Bruno, CA 1

MapLight Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$160 K1
FY202411$400 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MapLight Therapeutics, Inc.

Discuss MapLight Therapeutics, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of MapLight Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 6 insiders sold shares worth about $1,063,572 in 6 trades. Awards, option exercises and shares withheld for tax are not counted.

  • Mutual funds: 117 funds hold $211 millionautomatic update · Jul 31, 2026

    117 mutual funds in 1 country hold shares of MapLight Therapeutics, Inc. worth $211 million, about 16.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 52 funds added shares and 49 sold; on balance they bought $75 million. Share splits are not counted as trading.

How MapLight Therapeutics, Inc. compares in Biotechnology

  • Market cap$558 M · higher than 60% of 726
  • Price / book1.2× · lower than 74% of 534
  • FCF yield-24.8% · higher than 39% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
MapLight Therapeutics, Inc.🇺🇸$558 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Sep 15, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at MapLight Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show MapLight Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about MapLight Therapeutics, Inc.? Suggest a correction